Skip to Main Content

When the drug maker Novartis announced last month that it would cut 2,200 jobs, it framed the decision not as a retreat but as a restructuring. The goal, CEO Vas Narasimhan said, was to reshape the company to focus on “specialized and more personalized innovative medicines.”

Out with the company’s contact lens business, in with cancer immunotherapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!